Stanford University
Showing 461-480 of 2,015 Results
-
Dane Kawano
Ph.D. Student in Biology, admitted Autumn 2019
BioBorn and raised in Hawaii. Moved to Seattle, WA to study biology and biochemistry at the University of Washington. After graduating, I moved to Bethesda, MD to work at the NIH as an IRTA fellow. Currently in the Shen Lab studying microtubule biology in C. elegans neurons
-
Cameron S. Kay
Postdoctoral Scholar, Environmental Social Sciences
BioCameron S. Kay is a postdoctoral scholar in the Climate Cognition Lab at Stanford University. His research explores the psychological foundations of antisocial beliefs and behaviours, including why people believe in conspiracy theories, harbour prejudicial beliefs, and gaslight others. To support this work, he develops psychometrically sound scales and tools for improving data quality. Before joining Stanford, Cameron was a visiting assistant professor at Union College in Upstate New York. He earned his PhD in psychology with a specialization in quantitative research methods at the University of Oregon, where he also completed master’s degrees in psychology and journalism. He holds a BA in psychology from the University of British Columbia.
-
Mark A. Kay, M.D., Ph.D.
Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics
Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.
-
Debra Lee Kaysen
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Current Research and Scholarly InterestsMuch of my current research focus is on the development of testing of accessible, scaleable, and effective treatments for trauma-related disorders and related comorbidities (e.g. substance use disorders, HIV, mood disorders). This work has focused on addressing trauma-related disorders especially in underserved populations and settings. This includes research in rural communities, with Native American communities, and with sexual minorities. My research has had a strong impact on building an evidence base on adaptations of psychotherapies for PTSD and substance use disorders for diverse populations both within and outside the United States. Our findings demonstrate that complex cognitive behavioral psychotherapies like Cognitive Processing Therapy can be culturally adapted and delivered in challenging settings (conflict settings, high poverty environments) with significant and lasting change in PTSD, depression, and functioning. This has led to work adapting CPT for diverse populations within the United States (rural Native Americans, urban Latinos) and outside of it (Iraq, DRC). Other research has focused on treatment for PTSD/SUD. My research has also found support for the use of brief telehealth interventions to build treatment engagement and to reduce drinking among trauma-exposed populations. In addition, my work has been critical in testing the feasibility of novel trauma-focused interventions for use by those with PTSD and SUD, thus paving the road for more rigorous research studies.
Current PI'ed research studies include: 1) developing and evaluating a brief motivational interviewing intervention designed to increase treatment-seeking among military personnel with untreated PTSD; a two-arm randomized comparative effectiveness trial to evaluate prevention of HIV/STI sexual risk behavior by addressing PTSD through Narrative Exposure Therapy or substance use through Motivational Interviewing among Native American men and women with PTSD; and 3) a comparison of outcomes among patients randomized to initially receive pharmacotherapy or Written Exposure Therapy delivered in primary care as well as comparing outcomes among patients randomized to treatment sequences (i.e., switching and augmenting) for patients who do not respond to the initial treatment.
